

## APPENDIX.

## Contributing CCG Investigators, Institutions, and Grant Numbers

Institution	Investigator	Grant No.
University of California Medical Center, San Francisco, CA	Katherine Matthay	CA17829
Childrens Hospital and Medical Center, Seattle, WA	James Miser	CA10382
Childrens Hospital of Los Angeles, Los Angeles, CA	Jorge Ortega	CA02649
University of Minnesota Health Sciences Center, Minneapolis, MN	William Woods	CA07306
Childrens Hospital Medical Center, Cincinnati, OH	Robert Wells	CA26126
Harbor/UCLA and Miller Childrens Hospital, Torrance and Long Beach, CA	Jerry Finklestein	CA14560
University of California Medical Center, Los Angeles, CA	Stephen Feig	CA27678
Vanderbilt University School of Medicine, Nashville, TN	John Lukens	CA26270
University of British Columbia, Vancouver, Canada	Christopher Fryer	CA29013
Memorial Sloan-Kettering Cancer Center, New York, NY	Peter Steinherz	CA42764
Childrens Mercy Hospital, Kansas City, MO	Arnold Freeman	—
Childrens Hospital of Columbus, Columbus, OH	Frederick Ruymann	CA03750
Columbia Presbyterian College of Physicians and Surgeons, New York, NY	Sergio Piomelli	CA03526
Childrens Hospital of Pittsburgh, Pittsburgh, PA	Joseph Mirro	CA36015
James Whitcomb Riley Hospital for Children, Indianapolis, IN	Philip Breitfeld	CA13809
CCG Operations, Center, Arcadia, CA	W. Archie Bleyer and Daniel Stram	CA13539

## REFERENCES

1. Brodeur GM, Castleberry RP: Neuroblastoma. in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology, Philadelphia, PA, Lippincott, 1993, pp 739-767
2. Seeger RC, Villablanca JG, Matthay KK et al: Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastoma. *Prog Clin Biol Res* 366:527-533, 1991
3. Graham-Pole J, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. *J Clin Oncol* 9:152-158, 1991 (published erratum in *J Clin Oncol* 9:1094, 1991)
4. Philip T, Zucker JM, Bernard JL, et al: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? *J Clin Oncol* 9:1037-1044, 1991
5. Kushner BH, O'Reilly RJ, Mandell LR et al: Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. *J Clin Oncol* 9:274-279, 1991
6. Dini G, Lanino E, Garaventa A et al: Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: Report of 34 cases. *J Clin Oncol* 9:962-969, 1991
7. Seeger RC, Reynolds CP: Treatment of high risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. *Pediatr Clin North Am* 38:393-424, 1991
8. Glorieux P, Bouffet E, Philip I et al: Metastatic interstitial pneumonitis after autologous bone marrow transplantation: A consequence of reinjection of malignant cells? *Cancer* 1986; 58:2136-2139
9. Philip T, Zucker JM, et al: Bone marrow transplantation in an unselected group of 65 patients with stage IV neuroblastoma, in Dicke KA, Spitzer G, Jagannath S (eds): Autologous Marrow Transplantation: Proceedings of the Third International Symposium. Houston, TX, M.D. Anderson Hospital and Tumor Institute, 1987, pp 407-417
10. Moss TJ, Reynolds CP, Sather HN, et al: Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. *N Engl J Med* 324:219-226, 1991
11. Evans AE, D'Angio GJ, Randolph J: A proposed staging for children with neuroblastoma. *Cancer* 27:374-378, 1971
12. Shimada H, Chatten J, Newton WA, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. *J Natl Cancer Inst* 73:405-416, 1984
13. Chatten J, Shimada H, Sather HN, et al: Prognostic value of histopathology in advanced neuroblastoma: A report from the Childrens Cancer Study Group. *Hum Pathol* 19:1187-1198, 1988
14. Hann HWL, Evans AE, Siegel SE, et al: Prognostic importance of serum ferritin in patients with stages III and IV neuroblastoma: The Childrens Cancer Study Group experience. *Cancer Res* 45:2843-2848, 1985
15. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the *N-myc* oncogene with rapid progression of neuroblastomas. *N Engl J Med* 313:1111-1116, 1985
16. O'Leary MC, Sather HN, Ramsay NK, et al: Intensive chemotherapy for poor prognosis neuroblastoma. *Proc Am Assoc Cancer Res* 31:201, 1990 (abstr)
17. Brodeur GM, Seeger RC, Barrett A et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. *J Clin Oncol* 6:1874-1881, 1988
18. Reynolds CP, Seeger RC, Vo DD et al: Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. *Cancer Res* 46:5882-5886, 1986
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 53:457-481, 1958
20. Matthay KK, Atkinson JB, Stram DO, et al: Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: A Childrens Cancer Group pilot study. *J Clin Oncol* 11:2226-2233, 1993
21. Seeger RC, Moss TJ, Feig SA, et al: Bone marrow transplantation for poor prognosis neuroblastoma. *Prog Clin Biol Res* 271:203-213, 1988
22. Dini G, Philip T, Hartmann O, et al: Bone marrow transplantation for neuroblastoma: A review of 509 cases. *Bone Marrow Transplant* 4:42-46, 1989 (suppl 4)
23. D'Angio GJ, August C, Elkins W, et al: Metastatic neuroblastoma managed by supralesional therapy and bone marrow reconsti-

tution. Results of a four-institution Children's Cancer Study Group pilot study. *Prog Clin Biol Res* 175:557-563, 1985

24. Gorin NC: Collection, manipulation and freezing of haemopoietic stem cells. *Clin Haematol* 15:19-48, 1986

25. Herzig GP: Autologous marrow transplantation in cancer therapy, in Brown EB (ed) *Progress in Hematology*, vol 12. New York, NY, Grune & Stratton, 1981 pp 1-23

26. Sansone R, D, Martino D, Lanino E, et al: MYCN amplification does not affect survival of neuroblastoma patients treated with

autologous bone marrow transplantation. *Bone Marrow Transplant* 7:133-135, 1991 (suppl 3)

27. Stram DO, Matthay KK, O'Leary M, et al: Myeloablative chemoradiotherapy versus continued chemotherapy for high risk neuroblastoma. *Prog Clin Biol Res* 385:287-291, 1994

28. Seeger RC, Matthay KK, Villablanca JG, et al: Intensive chemoradiotherapy and autologous bone marrow transplantation (ABMT) for high risk neuroblastoma. *Proc Am Soc Clin Oncol* 10:310, 1991 (abstr)